Cecilia M. Shikuma to Treatment Outcome
This is a "connection" page, showing publications Cecilia M. Shikuma has written about Treatment Outcome.
Connection Strength
0.219
-
Souza SA, Chow DC, Walsh EJ, Ford S, Shikuma C. Pilot study on the safety and tolerability of extended release niacin for HIV-infected patients with hypertriglyceridemia. Hawaii Med J. 2010 May; 69(5):122-5.
Score: 0.068
-
Thao VP, Quang VM, Wolbers M, Anh ND, Shikuma C, Farrar J, Dunstan S, Chau NVV, Day J, Thwaites G, Le T. Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam. Medicine (Baltimore). 2015 Oct; 94(43):e1715.
Score: 0.025
-
Lin C, Grandinetti A, Shikuma C, Souza S, Parikh N, Nakamoto B, Kallianpur KJ, Chow D. The effects of extended release niacin on lipoprotein sub-particle concentrations in HIV-infected patients. Hawaii J Med Public Health. 2013 Apr; 72(4):123-7.
Score: 0.021
-
Phanuphak N, Ananworanich J, Teeratakulpisarn N, Jadwattanakul T, Kerr SJ, Chomchey N, Hongchookiat P, Mathajittiphun P, Pinyakorn S, Rungrojrat P, Praihirunyakit P, Gerschenson M, Phanuphak P, Valcour V, Kim JH, Shikuma C. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther. 2012; 17(8):1521-31.
Score: 0.020
-
McLinden RJ, Paris RM, Polonis VR, Close NC, Su Z, Shikuma CM, Margolis DM, Kim JH. Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS. 2012 Jan 02; 26(1):1-9.
Score: 0.019
-
Le T, Huu Chi N, Kim Cuc NT, Manh Sieu TP, Shikuma CM, Farrar J, Day JN. AIDS-associated Penicillium marneffei infection of the central nervous system. Clin Infect Dis. 2010 Dec 15; 51(12):1458-62.
Score: 0.018
-
Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007 Apr 23; 21(7):813-23.
Score: 0.014
-
Valcour V, Yee P, Williams AE, Shiramizu B, Watters M, Selnes O, Paul R, Shikuma C, Sacktor N. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection--The Hawaii Aging with HIV Cohort. J Neurovirol. 2006 Oct; 12(5):387-91.
Score: 0.013
-
Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther. 2006; 11(6):751-60.
Score: 0.013
-
Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, Arakaki R, Snyder S, Coombs RW, Bosch RJ, Spritzler J, Chernoff M, Aga E, Myers L, Schock B, Lederman MM. A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J Acquir Immune Defic Syndr. 2003 Mar 01; 32(3):281-6.
Score: 0.010